Merck Sharp + Dohme Corp.

N.v. Organon

Merck Sharp + Dohme B.v.

Msd Oss B.v.

Pharmacopeia Inc.

Paul David Ratcliffe

Yusheng Xiong

Clare London

Scott B Hoyt

Emma Louise Carswell

D Jonathan Bennett

Bheemashankar A Kulkarni

Andrew John Cooke

Jaiqiang Cai

Min K Park

Swapan Kumar Samanta

John K MacLean

Jerry Andrew Taylor

John MacLean

Koc-Kan Ho

Michael H Ohlmeyer

Fiona Jeremiah

Amjad Ali

Nasrin Ansari

Jeffrey John Letourneau

Brent Whitehead

Jiaqiang Cai

Steven G Kultgen

Irina Neagu

Andrew Cooke

Patrick Anthony Jokiel

Susan Elizabeth Napier

Yajing Rong

Julia Adam-Worrall

Ronald Palin

Rohit Saxena

Andrew Laird Roughton

Angus John Morrison

Jurgen Schulz

Duncan Robert McArthur

Takao Kiyoi

John Kinnard Ferguson MacLean

Michael Lo

Stuart John Francis

Archana Gupta

Thomas Russell Clarkson

Schulz Jurgen

Jeremiah Fiona

Duncan Robert Mcarthur

John Kinnaird Ferguson Maclean

Brent White-Head

D Jonathan Bennet

Jaiqiqang Cai

Emma Carswell

John Maclean

Jeffrey Letourneau

This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Pyrazolopyridyl compounds as aldosterone synthase inhibitors

This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Triazolopyridyl compounds as aldosterone synthase inhibitors

This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Imidazopyridyl compounds as aldosterone synthase inhibitors

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. 

Aldosterone synthase inhibitors

The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease. 

Heterocyclic derivatives

The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders. 

5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators

Disclosed herein are quinazolinone or isoquinolinone derivatives of formula I, or pharmaceutically acceptable salts or solvates thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising quinazolinone or isoquinolinone according to the present invention and its use in therapy.

Quinazolinone and isoquinolinone acetamide derivatives

Disclosed herein are indole derivatives of the formula (I) wherein each of the substitutents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the indole derivatives and use of the derivatives for the treatment of pain.

Indole derivatives

Growing community of inventors

Newhouse, United Kingdom

Paul David Ratcliffe